New York Eye and Ear Infirmary
Adjust: Text Size Make Font Smaller Make Font Larger Print this Page: Normal Print Friendly Large Print Friendly Accessibility Info

CLINICAL EFFICACY OF INTRAVITREAL ADMINISTRATION OF BEVACIZUMAB COMBINED WITH NAVIGATED LASER (NAVILAS) TREATMENT IN PATIENTS WITH CLINICALLY SIGNIFICANT MACULAR EDEMA Protocol CAVNAV-2

This study is currently recruiting participants.

Purpose: The purpose of this study is to evaluate clinical outcomes with combination Bevacizumab and navigated laser treatment in eyes with CLINICALLY SIGNIFICANT MACULAR EDEMA (CSME) compared to Bevacizumab monotherapy. The effectiveness of Navilas laser treatment following Bevacizumab injection will be evaluated, including on whether Navilas navigated laser treatment reduces the number of Bevacizumab injections necessary to stabilize visual gains in patients with CSME.

Eligibility:

  • This is a 1 year trial.  DME patients could be naïve or previously treated but need to comply with the criteria below.
  • Age ≥ 18 years with CSME, Diagnosis of diabetes mellitus (type 1 or type 2)
  • Central foveal thickness > 250 microns at baseline (based on Spectralis SD OCT)
  • Best corrected visual acuity between 20/400 and 20/40

Contact Information

Richard Rosen, MD, Retina Specialist

Priya Mehta, Clinical Research Coordinator at (212) 979-4672 or pmehta@nyee.edu.

 

Home > Current Research > Clinical Trials in Ophthalmology > CLINICAL EFFICACY OF INTRAVITREAL ADMINISTRATION OF BEVACIZUMAB COMBINED WITH NAVIGATED LASER (NAVILAS) TREATMENT IN PATIENTS WITH CLINICALLY SIGNIFICANT MACULAR EDEMA Protocol CAVNAV-2